Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinical situation is an urgent task of clinical oncology...

Full description

Bibliographic Details
Main Authors: Irina V. Kolyadina, Natalia R. Abidova, Arshak A. Akopyan, Galina V. Antonova, Oksana I. Arapova, Elvira A. Bobrova, Larisa V. Bolotina, Chulpan K. Valiakhmetova, Anna V. Vasilevskaya, Lyubov Y. Vladimirova, Mikhail V. Volkonskiy, Inna P. Ganshina, Irina E. Gudkova, Alexandr S. Dergunov, Irina V. Evstigneeva, Viktoria S. Egurenkova, Aleksei V. Emshanov, Lyudmila G. Zhukova, Elena V. Zueva, Elena V. Karabina, James J. Kolokolov, Svetlana V. Kuzmicheva, Olesya A. Kuchevskaya, Ivan A. Luev, Ksenia S. Maistrenko, Elena V. Markizova, Vasily V. Marfutov, Sergey P. Medvedev, Yulia I. Merzlikina, Tatyana A. Nersesova, Elena G. Ovchinnikova, Svetlana A. Orlova, Natalia Y. Samaneva, Olesya A. Stativko, Anna E. Storozhakova, Daniil L. Stroyakovskiy, Alexander V. Sultanbaev, Asiat I. Tekeeva, Natalia V. Fadeeva, Alina N. Fedorova, Oksana M. Shalaeva, Irina A. Shangina, Oksana N. Shirokova, Alisa R. Shumskikh, Mariam Z. Yakubova
Format: Article
Language:Russian
Published: IP Habib O.N. 2021-05-01
Series:Современная онкология
Subjects:
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/70308/51242